Alternative Instrumental Treatments in BPH
Transurethral Needle Ablation (TUNATM)
Chapple C.R.a · Issa M.M.b · Woo H.c
A Critical Review of Radiofrequency Thermal Therapy in the Management of Benign Prostatic Hyperplasia
Departments of Urology, bThe Royal Hallamshire Hospital, Sheffield; UK;bEmory University School of Medicine, The Emory Clinic (Urology), Atlanta, Ga., USA; cWestern Urology, Sydney, New South Wales, Australia
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Radiofrequency thermal therapy of the prostate is a new minimally invasive treatment for symptomatic benign prostatic hyperplasia (BPH). The procedure is called transurethral needle ablation (TUNATM). With TUNA, the inner region of the prostate is selectively ablated with temperatures approaching 90–100°C while the prostatic urothelium is preserved. The objective of this article is to discuss the basics of radiofrequency energy, instrumentation, surgical techniques, and to present an update of the clinical results as it applies to the treatment of BPH.
- Issa MM: Transurethral needle ablation of the prostate: Report of initial United States Clinical Trial. J Urol 1996;156:413–419.
Issa MM, Oesterling JE: Transurethral needle ablation (TUNA): An overview of radiofrequency thermal therapy for the treatment of benign prostatic hyperplasia. Curr Opin Urol 1996;6:20–27.
- Bruskewitz R, Issa MM, Roehrborn CG, Naslund MJ, Perez-Marrero R, Shumaker BP, Oesterling JE: A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1998;159:1588–1594.
- Roehrborn CG, Issa MM, Bruskewitz RC, Naslund MJ, Oesterling JE, Perez-Marrero R, Shumaker BP, Narayan P: Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter US study. Urology 1998;51:415–421.
- Steele GS, Sleep DJ: Transurethral needle ablation of the prostate: A urodynamic based study with two year follow-up. J Urol 1997;158:1834–1838.
- Campo B, Bergamaschi F, Corrada P, Ordesi G: Transurethral needle ablation (TUNA) of the prostate: A clinical and urodynamic evaluation. Urology 1997;49:847–850.
- Schulman CC, Zlotta AR, Rasor JS, Hourriez L, Noel JC, Edwards SD: Transurethral needle ablation (TUNA): Safety, feasibility, and tolerance of a new office procedure for treatment of benign prostatic hyperplasia. Eur Urol 1993;24:415–423.
- Schulman CC, Zlotta AR: Transurethral needle ablation of the prostate for treatment of benign prostatic hyperplasia: Early clinical experience. Urology 1995;45:28–33.
- Schulman CC, Zlotta AR: Transurethral needle ablation (TUNA) of the prostate: Clinical experience with two years follow-up in patients with benign prostatic hyperplasia (BPH). J Urol 1997;157:98.
Giennakopoulos X, Grammeniatis E, Gartzios A, Pappas G: Transurethral needle ablation (TUNA) of the prostate: Preliminary results using the new generation TUNA III catheter on patients with symptomatic BPH controlled by a series of 50 patients using TUNA II device. Eur Urol 1996;30:986.
- Ramon J, Lynch TH, Eardley I, Ekmans P, Frick J, Jungwirth A, Pillai M, Wiklund P, Goldwasser B, Fitzpatrick JM: Transurethral needle ablation of the prostate for the treatment of benign prostatic hyperplasia: A collaborative multicentre study. Br J Urol 1997;80:128–135.
- Rosario DJ, Woo H, Potts KL, Cutinha PE, Hastie KJ, Chapple CR: Safety and efficacy of transurethral needle ablation of the prostate for symptomatic outlet obstruction. Br J Urol 1997;80:579–586.
Virdi JS, Sriram R, Pandit A: Transurethral needle ablation of the prostate (TUNA): A prospective study. J Urol 1997;157(4):146 (abstract).
Millard RJ, Harewood LM, Tamaddon K: A study of the efficacy and safety of transurethral needle ablation (TUNA) for benign prostatic hyperplasia. Neurol Urodynam 1996;15:916–929.
- de la Rosette JJMCH, de Wildt MJAM, Hofner K, Carter SStC, Debruyne FMJ, Tubaro A: High-energy thermotherapy in the treatment of benign prostatic hyperplasia: Results of the European BPH study group. J Urol 1996;156:97–102.
- Muschter R, Hofstetter A: Technique and results of interstitial laser coagulation. World J Urol 1995;13:109–114.
- Bihrle R, Foster RS, Sanghvi NT, Donohue JP, Hood PJ: High-intensity focused ultrasound for the treatment of benign prostatic hyperplasia: Early United States clinical experience. J Urol 1994;151:1271–1275.
- Calkins H, Langberg J, Sousa J, El-Atassi R, Leon A, Kou W, Kalbfleisch S, Moraday F: Radiofrequency catheter ablation of accessory atrioventricular connections in 250 patients. Abbreviated therapeutic approach to Wolff-Parkinson-White syndrome. Circulation 1992;85:1337–1346.
Organ LW: Electrophysiologic principles of radiofrequency lesion-making. International symposium on radiofrequency lesion-making procedures, Chicago, Illinois, 1976. Appl Neurophysiol 1976;39:69–76.
- Rasor JS, Zlotta AR, Edwards SD, Schulman CC: Transurethral needle ablation (TUNA): thermal gradient mapping and comparison of lesion size in a tissue model and in patients with benign prostatic hyperplasia. Eur Urol 1993;24:411–414.
- Goldwasser B, Ramon J, Engleberg S, Ohad D, Sharkey H, Struhl B, Rasor JS, Edwards SD: Transurethral needle ablation (TUNA) of the prostate using low-level radiofrequency energy: An animal experimental study. Eur Urol 1993;24:400–405.
- Ramon J, Goldwasser B, Shenfeld O, Engleberg S, Rasor JS, Edwards SD: Needle ablation using radiofrequency current as a treatment for benign prostatic hyperplasia: Experimental results in ex vivo human prostate. Eur Urol 1993;24:406–610.
Issa MM, Oesterling JE, Roehrhorn CG, Bruskewitz R, Naslund MJ, Perez-Marrero R, Shumaker BP: Long-term follow-up of a prospective, randomized clinical United States trial comparing transurethral needle ablation (TUNA) to transurethral resection of the prostate (TURP) for the treatment of benign prostatic hyperplasia (BPH). Min Inv Ther Allied Technol 1997;6:62.
- Harewood LM, Laurence KC, O’Connell HE, Pope AJ: Transurethral needle ablation of the prostate (TUNA): Clinical results and ultrasound, endoscopic, and histologic findings in pilot study of patients in urinary retention. J Endourol 1995;9:407–412.
- Zlotta AR, Peny MO, Matos C, Schulman CC: Transurethral needle ablation of the prostate: Clinical experience in patients with urinary retention. Br J Urol 1996;77:391–397.
Issa MM, Wojno KJ, Oesterling JE, Pilat MJ, Singleton TP: Histopathologic and biochemical study of the prostate following transurethral needle ablation (TUNA): Insight to the mechanism of improvement in BPH symptoms. J Endourol 1996;10:A109.
- Zlotta AR, Raviv G, Peny M-O, Noël J-C, Haot J, Schulman CC: Possible mechanism of action of transurethral needle ablation of the prostate on benign prostatic hyperplasia: A neurohistochemical study. J Urol 1997;157:894–899.
- Peranchino M, Bozzo W, Puppo P, Vitali A, Ardoino S, Ferro MA: Does transurethral thermotherapy induce a long-term alpha blockade? An immunohistochemical study. Eur Urol 1993;23:299–301.
Naslund MJ: A cost comparison of TUNA vs. TURP. J Urol 1997;157:155.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.